Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PIPE 791 for idiopathic pulmonary fibrosis is currently recruiting to assess its efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PIPE-791

Snippet

Sponsor: Contineum Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: RECRUITING